Systemic Lupus Erythematosus
📧 Sign up to get email alerts when something new happens for Systemic Lupus Erythematosus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-10-27Clinical Trial Update: Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus [Phase 3]
Phase 3 clinical trial reappraising therapies for refractory autoimmune hemolytic anemia in systemic lupus erythematosus is in progress, wit…
-
FDA approval · 2021-10-22FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approves a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2021-10-15Clinical Trial Update: Single Ascending Dose Study of AMG 570 in Healthy Subjects [Phase 1]
This clinical trial update reports the completion of a Phase 1 single ascending dose study of AMG 570 in healthy subjects, with results post…
-
FDA approval · 2021-09-14FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for hydroxychloroquine sulfate from Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) [Phase 1, Phase 2]
Phase 1/2 trial exploring PPAR-γ agonists for immunomodulation and vascular prevention in systemic lupus erythematosus has completed with re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-08-23FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Ipca Laboratories Limited)
The FDA approved a supplemental application for hydroxychloroquine sulfate from Ipca Laboratories Limited, approving changes to an already-a…
-
FDA approval · 2021-08-11FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Cellcept (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for mycophenolate mofetil submitted by Hikma Pharmaceuticals USA Inc., updating the product info…
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Mycophenolate mofetil from Mylan Pharmaceuticals Inc., updating the regulatory status for th…
-
FDA approval · 2021-07-30FDA Approved: SAPHNELO — Original Application (AstraZeneca Pharmaceuticals LP)
FDA approved SAPHNELO (anifrolumab-fnia) from AstraZeneca in its original application for adults with moderate to severe systemic lupus eryt…
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: Reducing Disparities in Medication Adherence in SLE [NA]
A completed Duke University–sponsored clinical trial on reducing disparities in medication adherence for systemic lupus erythematosus; resul…
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases [Phase 2]
Phase 2 clinical trial evaluating low-dose IL-2 to induce regulatory T cells in various autoimmune and inflammatory diseases; trial complete…
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord [Phase 1, Phase 2]
Clinical trial evaluating allogeneic mesenchymal stem cells from umbilical cord for refractory systemic lupus erythematosus in Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus [Phase 2]
A Phase 2 efficacy and safety study of Dapirolizumab Pegol (DZP) in systemic lupus erythematosus has completed with results posted in 2021.
-
FDA approval · 2021-04-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for mycophenolate mofetil from Hikma Pharmaceuticals USA Inc., updating or expanding its labeled ind…
-
FDA approval · 2021-04-21FDA Approved: MYCOPHENOLIC ACID — Supplemental Application (Slate Run Pharmaceuticals, LLC)
FDA approved a supplemental application for mycophenolic acid from Slate Run Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients [Phase 2]
Phase 2 clinical trial updating the efficacy and safety of CS20AT04 (allogeneic bone marrow-derived stem cell) in patients with systemic lup…
-
CLINICAL_TRIALS trial_result · 2021-03-23Clinical Trial Update: An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus [Phase 2]
Open-label Phase 2 trial evaluating daratumumab in adults with moderate to severe systemic lupus erythematosus.
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) [Phase 2]
Phase 2a trial of RSLV-132 in systemic lupus erythematosus has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus [Phase 2]
Phase 2 trial evaluating CC-220 (iberdom, pomalidomide analog) for efficacy and safety in active systemic lupus erythematosus completed with…
-
CLINICAL_TRIALS research · 2021-01-22Clinical Trial Update: Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells [Phase 1, Phase 2]
Phase 1/2 trial evaluating pooled allogenic mesenchymal stem cells for systemic lupus erythematosus has completed.
-
FDA label_change · 2021-01-15FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA issued a supplemental approval for mycophenolate mofetil (Hikma) to update the drug's labeling under an existing approval.
-
FDA approval · 2021-01-15FDA Approved: MYCOPHENOLIC ACID — Supplemental Application (Archis Pharma LLC)
The FDA approved Archis Pharma LLC's supplemental application for mycophenolic acid (generic), indicating an approved modification to the ma…
-
FDA approval · 2021-01-15FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for a generic version of mycophenolate mofetil from Concord Biotech Limited.
-
FDA approval · 2021-01-15FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Mycophenolate mofetil (Sandoz Inc), signaling an updated/expanded use or labeling for the produc…